Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
HBM Healthcare Investments
AddedFeb 13, 2024
UpdatedJun 28, 2026
HBM Healthcare Investments

HBM Healthcare Investments

Operating

HBM Healthcare Investments AG is a Swiss venture capital firm, investing in emerging biotech and medical sectors, focusing on high-potential private companies.

Location
Zug, Zug, CH
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Investments

Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Series B$168MOctober 2022
Series A$218MDecember 2021
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Series A$200MJune 2022
Series AOctober 2021
Numab
Numab

Total Raised

$122M

Rounds

3

Series CDecember 2022
Series C$100MMay 2021
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Valo Health
Valo Health

Total Raised

$460M

Rounds

5

Series COctober 2022
Mahzi Therapeutics
Mahzi Therapeutics

Total Raised

$47.3M

Rounds

2

Series AOctober 2022
Series A$47.3MOctober 2021
Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Convertible NoteOctober 2022
Series CSeptember 2021
Shape Memory Medical
Shape Memory Medical

Total Raised

$13.6M

Rounds

8

Convertible NoteJuly 2022
Vascular Dynamics
Vascular Dynamics

Total Raised

$105.1M

Rounds

10

Series Unknown$20MJuly 2022
Series DMay 2022
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Series AOctober 2021
Karius
Karius

Total Raised

$254M

Rounds

6

Series BMarch 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Neuron23
Neuron23

Total Raised

$213.5M

Rounds

4

Series CNovember 2021
Antiva Biosciences
Antiva Biosciences

Total Raised

$140.3M

Rounds

9

Series D$31MNovember 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021